Please assess the completion status of the following clinical trial:

Trial Title: Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 37 weeks gestation~* Exposure to opiates in utero~* Demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment~Exclusion Criteria:~* Major congenital malformations and/or intrauterine growth retardation~* Medical illness requiring intensification of medical therapy. This includes, but is not limited to suspected sepsis requiring antibiotic therapy.~* Hypoglycemia requiring treatment with intravenous dextrose.~* Bilirubin \>20 mg/dL (The need for phototherapy is not exclusionary)~* Concomitant benzodiazepine or severe alcohol abuse , self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother 30 days prior to birth,~* Concomitant use of Cytrochrom (CYP) 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment~* Seizure activity or other neurologic abnormality~* Breast feeding~* Inability of mother to give informed consent due to co-morbid psychiatric diagnosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sublingual buprenorphine (Type: EXPERIMENTAL): This is the group that received active sublingual buprenorphine and placebo for oral morphine
- oral morphine (Type: ACTIVE_COMPARATOR): This is the group that received active oral morphine and placebo for sublingual buprenorphine

Based on this trial design, predict the completion outcome and termination type (if applicable).